NASDAQ:RETA Reata Pharmaceuticals - RETA News Today Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Reata Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $90.92 +0.90 (+1.00%) (As of 03/31/2023 12:00 AM ET) Add Compare Share Share Today's Range$88.01▼$93.1650-Day Range$30.85▼$93.1752-Week Range$18.47▼$95.00Volume851,682 shsAverage Volume1.13 million shsMarket Capitalization$3.34 billionP/E RatioN/ADividend YieldN/APrice Target$96.89 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Get Reata Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RETA and its competitors with MarketBeat's FREE daily newsletter. Email Address RETA Media Mentions By Week RETA Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RETA News Sentiment▼0.190.47▲Average Medical News Sentiment RETA News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RETA Articles This Week▼121▲RETA Articles Average Week All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineReata Pharmaceuticals, Inc. (NASDAQ:RETA) to Post FY2022 Earnings of ($8.54) Per Share, Cantor Fitzgerald Forecastsmarketbeat.com - March 30 at 6:52 AMQuent Capital LLC Acquires New Holdings in Reata Pharmaceuticals, Inc. (NASDAQ:RETA)marketbeat.com - March 30 at 5:28 AMReata Pharmaceuticals, Inc. (NASDAQ:RETA) Given Average Recommendation of "Moderate Buy" by Brokeragesmarketbeat.com - March 27 at 4:41 AMThe Stock That Tripled in a Day...And May Not Be Donemarketbeat.com - March 7 at 6:55 AMReata Pharmaceuticals, Inc. (NASDAQ:RETA) Given Consensus Rating of "Moderate Buy" by Analystsamericanbankingnews.com - April 1 at 4:44 AMReata Pharmaceuticals, Inc. (NASDAQ:RETA) Forecasted to Earn FY2022 Earnings of ($8.54) Per Shareamericanbankingnews.com - April 1 at 1:26 AMReata Pharmaceuticals (NASDAQ:RETA) PT Raised to $138.00americanbankingnews.com - March 29 at 2:46 AMWhere Reata Pharmaceuticals Stands With Analystsmarkets.businessinsider.com - March 27 at 1:46 PMREATA PHARMACEUTICALS INVESTIGATION INITIATED By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Reata Pharmaceuticals, Inc ...businesswire.com - March 5 at 10:07 PMREATA PHARMACEUTICALS INVESTIGATION INITIATED By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Reata Pharmaceuticals, Inc. - RETAbusinesswire.com - March 3 at 9:40 PMPlano-based Reata Pharmaceuticals secures FDA approval for first-of-its-kind ultra-rare disease treatmentbizjournals.com - March 2 at 2:35 PMWhy Reata Pharmaceuticals Stock Skyrocketed This Weekfinance.yahoo.com - March 2 at 2:35 PMReata (RETA) Stock Jumps as FDA Approves Rare Disease Drugfinance.yahoo.com - March 2 at 9:35 AMHot Stocks: RETA nearly triples on FDA approval; FSLR surges on earnings; NVAX, MQ plungemsn.com - March 1 at 6:33 PMU.S. FDA approves Reata's rare genetic disorder drugreuters.com - March 1 at 8:32 AMReata Skyrockets on FDA Approval for Friedreich’s Ataxia Drugmsn.com - March 1 at 8:32 AMReata Soars on Approval for Rare Disorder Drug. Its Pipeline Value Impresses Analysts.barrons.com - March 1 at 8:32 AMFirst Week of April 21st Options Trading For Reata Pharmaceuticals (RETA)nasdaq.com - February 19 at 6:17 PMThe Nasdaq Is Rebounding: 2 Supercharged Growth Stocks to Buy in Februaryfinance.yahoo.com - February 1 at 12:40 PMReata Pharmaceuticalsforbes.com - January 25 at 1:13 PMReata Pharmaceuticals (NASDAQ: RETA)fool.com - January 14 at 11:35 PMReata Pharmaceuticals, Inc. (NASDAQ:RETA) Q3 2022 Earnings Call Transcriptfinance.yahoo.com - December 31 at 6:20 PMReata Pharmaceuticals, Inc. (NASDAQ:RETA) Q3 2022 Earnings Call Transcriptfinance.yahoo.com - December 31 at 6:20 PMReata Pharmaceuticals (NASDAQ:RETA) shareholders have endured a 84% loss from investing in the stock three years agofinance.yahoo.com - December 22 at 12:21 PMReata (RETA) Q3 Earnings Beat, Stock Up on Pipeline Updatesfinance.yahoo.com - November 9 at 12:36 PMReata rises 15% as omaveloxolone moves ahead in FDA review process; plans EU filingseekingalpha.com - November 8 at 2:08 PMWhy Reata Pharmaceuticals Stock Is Soaring Todayfinance.yahoo.com - November 8 at 2:08 PMReata Pharmaceuticals, Inc. Announces Third Quarter 2022 Financial Results and Provides an Update on Clinical Development Programsfinance.yahoo.com - November 8 at 9:07 AMReata Pharmaceuticals, Inc. to Report Third Quarter 2022 Financial Results and to Provide an Update on Clinical Development Programs on November 8, 2022finance.yahoo.com - November 1 at 2:15 AM2 On-Fire Biotech Stocks That Are Crushing the Bear Marketfinance.yahoo.com - October 31 at 11:20 AMWhy Is Reata Pharmaceuticals (RETA) Stock Up 15% Today?investorplace.com - October 14 at 3:02 PMNasdaq Tumbles Over 200 Points; Crude Oil Falls Sharplymarkets.businessinsider.com - October 14 at 1:22 PMReata Pharma Spikes 15%nasdaq.com - October 14 at 1:22 PMReata : FDA Doesn't Plan To Hold Meeting To Discuss NDA For Omaveloxolone For Friedreich's Ataxianasdaq.com - October 14 at 3:04 AMReata Pharmaceuticals Announces that the FDA Does Not Plan to Hold an Advisory Committee Meeting to Discuss the NDA for Omaveloxolone for Friedreich’s Ataxiafinance.yahoo.com - October 13 at 5:01 PMRETA Reata Pharmaceuticals, Inc.seekingalpha.com - October 1 at 11:18 AMInvestors in Reata Pharmaceuticals (NASDAQ:RETA) from a year ago are still down 76%, even after 13% gain this past weeknasdaq.com - September 13 at 9:43 PMMoore Kuehn, PLLC Encourages Investors of Reata Pharmaceuticals, Inc. to Contact Law Firmbenzinga.com - September 12 at 3:39 PMReata Pharmaceuticals Increuters.com - September 10 at 12:53 PM2RETA : Reata Pharmaceuticals Whale Trades Spottedbenzinga.com - September 8 at 3:32 PMWhy Is Kodiak Sciences Inc. (KOD) Down 23.8% Since Last Earnings Report?finance.yahoo.com - September 8 at 3:32 PMReata Pharmaceuticals Announces Participation in the Citi 17th Annual BioPharma Conferencefinance.yahoo.com - September 6 at 5:59 PMTime To Worry? Analysts Just Downgraded Their Reata Pharmaceuticals, Inc. (NASDAQ:RETA) Outlookfinance.yahoo.com - August 14 at 9:59 AMReata Pharmaceuticals Announces Three Month Extension of the Review Period for New Drug Application for Omaveloxolone for the Treatment of Friedreich’s Ataxiafinance.yahoo.com - August 9 at 7:20 AMReata Pharmaceuticals, Inc.'s (RETA) CEO Warren Huff on Q2 2022 Results - Earnings Call Transcriptseekingalpha.com - August 8 at 4:12 PMReata drops 33%, most since December; Goldman sees favorable risk reward profileseekingalpha.com - August 8 at 4:12 PMReata Pharmaceuticals, Inc. (RETA) Reports Q2 Loss, Lags Revenue Estimatesfinance.yahoo.com - August 8 at 4:12 PMWhy Reata Pharma Shares Are Trading Lower After Q2 Earnings Update?finance.yahoo.com - August 8 at 4:12 PMReata Pharmaceuticals Earnings Previewbenzinga.com - August 5 at 12:45 PMReata extends gains as Citi welcomes regulatory win for lead assetseekingalpha.com - May 27 at 4:38 PMFDA grants priority review to Reata's rare disease drugfinance.yahoo.com - May 26 at 7:01 PMReata Pharmaceuticals, Inc. (NASDAQ:RETA) Given Consensus Recommendation of "Buy" by Analystsamericanbankingnews.com - May 6 at 8:52 AMReata Pharmaceuticals, Inc. to Report First Quarter 2022 Financial Results and to Provide an Update on Clinical Development Programs on May 10, 2022finance.yahoo.com - May 2 at 8:24 PMMoore Kuehn, PLLC Encourages Investors of ALEC, RETA, ASXM, and PTCT to Contact Law Firmapnews.com - April 8 at 4:19 AM Get Reata Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RETA and its competitors with MarketBeat's FREE daily newsletter. Email Address This page (NASDAQ:RETA) was last updated on 4/1/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.